Skip to main content

Table 1 Baseline demographic characteristics and clinical parameters among three patient groups – the axial psoriatic arthritis, ankylosing spondylitis, and control groups

From: Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study

Parameter Axial psoriatic arthritis Ankylosing spondylitis Control
Number of patients 15 15 10
Age in years (mean ± SD) 38.6 ± 7.93 33.9 ± 8.28 40.0 ± 11.6
Duration of back pain - years (mean ± SD) 4.5 ± 1.3 5.4 ± 1.4 5.6 ± 1.7
Gender (female %) 60 46.7 60
CRP (mg/L) 9.00 ± 4.74 7.27 ± 3.61 4.00 ± 1.56
VAS (mean ± SD) 6.60 ± 1.12 6.47 ± 1.13 6.60 ± 1.51
ASQOL (mean ± SD) 11.8 ± 4.19 11.9 ± 3.74 10.0 ± 1.49
BASFI (mean ± SD) 6.40 ± 1.52 6.06 ± 1.49 4.14 ± 1.53
BASDAI (mean ± SD) 5.95 ± 1.24 5.86 ± 1.32 5.18 ± 1.07
ASDAS (mean ± SD) 3.81 ± 0.61 3.75 ± 0.55 2.82 ± 0.67
  1. There were no significant differences (p > 0.05) in the parameters listed in Table 1 between patients with axial psoriatic arthritis (AxPsA) and patients with ankylosing spondylitis (AS). Similarly, there were no significant differences (p > 0.05) in age, gender, visual analogue scale (VAS) spinal pain score, Ankylosing Spondylitis Quality of Life (ASQoL) or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with AxPsA or AS compared with controls
  2. CRP C-reactive protein, BASFI Bath Ankylosing Spondylitis Functional Index, ASDAS Ankylosing Spondylitis Disease Activity Score